Genetically engineered coxsackievirus, and pharmaceutical composition

Provided is a genetically engineered coxsackievirus which has improved safety and/or aggressiveness and can be used in an oncolytic virotherapy. Provided is a genetically engineered coxsackievirus, which contains a mutant genome and of which the proliferation in a normal cell is suppressed, wherein the mutant genome has such a structure that at least one polynucleotide comprising a target sequence miR-34a and/or a target sequence miR-34c is inserted into the genome of wild-type coxsackievirus B3 (CVB3-WT).